ReviewAnnals of biomedical engineering2026
Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.
Review in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Benzimidazole derivatives as dual EGFR and BRAFRSC advances · 2026Article
- Physicochemical Determinants of Bioactivity in Acacia Gum-Derived Silver Nanoparticles: Enhanced Selective Toxicity Toward MCF-7 Breast Cancer Cells.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance, which arises from a variety of biological mechanisms such as drug efflux by ATP-binding cassette transporters, epithelial-to-mesenchymal transition (EMT), the presence of cancer stem cells (CSCs), immune system evasion, and changes in the tumor microenvironment (TME), poses serious treatment challenges for breast cancer. This paper offers a thorough analysis of various resistance mechanisms, going into great detail into the molecular, cellular, and genetic contributors. We next look at how nanotechnology-based approaches, such multifunctional nanocarriers, smart nanoparticle systems, and targeted drug delivery, can be developed to get around these resistance mechanisms, building on this biological basis. The use of particular nanotechnology platforms (such as liposomes, micelles, and dendrimers) to target CSCs, circumvent efflux pumps, alter immunological responses, and improve treatment precision is highlighted. Important issues in clinical translation and regulatory considerations are also covered in the study. This two-part investigation seeks to improve therapeutic outcomes for drug-resistant breast cancer by bridging the gap between molecular insight and nanotechnological innovation.
Indexed as
Identifiers
41501437What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.